On February 7, 2025, Nevro Corp was acquired by Globus ... that was initially anticipated based on clinical trial outcomes. The U.S. SCS market remains highly competitive, with larger companies ...

Emerging treatment therapies targeting conditions earlier in the care continuum have been impacting demand for Nevro’s prized SCS portfolio. The company’s own SI offerings are solutions for ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European ... as well as U.S. trial procedures, declined in the fourth quarter. However, NVRO is likely ...

U.S. permanent implant procedures decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial ... treatment. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year ... pain management platform that powers the HFX iQ spinal cord ...